Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy
Phase II Trial of Natalizumab for Prevention of Immune Effector Cell Associated Neurologic Syndrome (ICANS) in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy for B-Cell Hematologic Malignancies
This phase II studies how well natalizumab works in preventing immune effector cell associated neurologic syndrome (ICANS) in patients with diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL) that has come back after a period of improvement (recurrent) or that does not respond to treatment (refractory) receiving chimeric antigen receptor (CAR) T-cell therapy. A major complication of CAR T-cell therapy is ICANS. ICANS is inflammation of the brain or nerves. ICANS currently requires high-dose corticosteroid treatment which can inhibit CAR T-cell response. Natalizumab prevents immune cells from traveling from the blood to the fluid around the brain, which is a process thought to play a major role in CAR T-cell related brain injury. Natalizumab may be safe and effective in decreasing the frequency of severe ICANS in patients with DLBCL or MCL receiving CAR T-cell therapy.
研究概览
地位
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Tracey Churay
- 电话号码:1-800-865-1125
- 邮箱:tchuray@med.umich.edu
学习地点
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
- 招聘中
- University of Michigan Rogel Cancer Center
-
首席研究员:
- Monalisa Ghosh
-
接触:
- Tracey Churay
- 电话号码:800-865-1125
- 邮箱:tchuray@med.umich.edu
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Patient must be ≥ 18 years of age at the time of signing informed consent (ICF)
- Patient must understand and voluntarily sign the ICF prior to conduct of any study-related assessments or procedures
- Patient must be willing to adhere to the study visit schedule and other protocol requirements
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- Patient must be eligible per institutional criteria for therapy with commercial axicabtagene ciloleucel or brexucabtagene autoleucel for treatment of relapsed or refractory diffuse large B-cell lymphoma or mantle cell lymphoma
- Per institutional protocol: Females and males of childbearing potential must be willing to abstain from heterosexual activity or to use 2 forms of effective methods of contraception from the time of informed consent until 12 months (female) or 4 months (males with female partners of reproductive potential) after the cyclophosphamide infusion. The two contraception methods can consist of two barrier methods or a barrier method plus a hormonal method. Female participants must agree to inform their male partners that they must use the methods of birth control required by the protocol. The use of intrauterine devices is excluded due to the risk of infection or bleeding
Exclusion Criteria:
-
Uncontrolled systemic fungal, bacterial, viral, or other infection despite appropriate antibiotics or treatment
- Patients with infections controlled on antibiotics are not excluded
-
Prior history or current infection with John Cunningham (JC) virus
-
Active hepatitis B or C (latent hepatitis B will not be excluded), or HIV. Entecavir prophylaxis can be used for latent hepatitis B. Patients' viral load must be undetectable per quantitative polymerase chain reaction (PCR) and/or nucleic acid testing at screening
-
Bilirubin: ≥ 2.0 x upper limit of normal (ULN), unless attributed to Gilbert's Syndrome or to the patient's primary malignancy
-
Aspartate aminotransferase (AST): ≥ 5 x ULN, alanine aminotransferase (ALT): ≥ 5 x ULN
-
Active concurrent autoimmune disease requiring immunosuppressive therapy
-
Active central nervous system (CNS) lymphoma
-
Active clinically relevant central nervous system disease including but not limited to:
- Seizures/epilepsy
- Stroke within the past 12 months, or unstable neurologic deficits within the past 12 months
- Cerebral edema
- Aphasia
- Severe brain injury
- Cerebellar disease
- Documented history of dementia by clinical diagnosis
- Parkinson's disease
- Psychosis
-
Pregnant or nursing females
-
History of or active progressive multifocal leukoencephalopathy (PML)
-
Prior history or active herpes encephalitis or meningitis infection
-
Current treatment with any other agents for prophylaxis of CRS or ICANS, including investigational agents. Use of antiseizure medications does not exclude patients
-
History of prior exposure to natalizumab due to risk of neutralizing antibody formation
-
History of hypersensitivity reaction to natalizumab or the formulation excipients
-
Consider adding: History of, or a concurrent, clinically significant illness, medical condition or laboratory abnormality that, in the investigator's opinion, could affect the conduct of the study
学习计划
研究是如何设计的?
设计细节
- 主要用途:支持治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Supportive care (SOC conditioning & CAR-T, natalizumab)
Patients receive SOC conditioning therapy consisting of fludarabine IV and cyclophosphamide IV on days -4 and -3. Patients then receive natalizumab IV over 1 hour on day -1, followed by SOC CAR T-cell therapy with axicabtagene ciloleucel or brexucabtagene autoleucel on day 0. Patients also undergo PET/CT and blood sample collection throughout the study. |
Given IV
其他名称:
Undergo collection of blood
其他名称:
Undergo PET/CT
其他名称:
Given IV
其他名称:
Undergo PET/CT
其他名称:
Given axicabtagene ciloleucel
其他名称:
Given brexucabtagene autoleucel
其他名称:
Given IV
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Occurrence of chimeric antigen receptor therapy (CAR-T)-associated neurotoxicity (immune effector cell associated neurotoxicity syndrome [ICANS])
大体时间:Up to CAR-T day +28
|
Any grade per American Society for Transplantation and Cellular Therapy Cytokine Release Syndrome (ASTCT) criteria. Will be considered binary and the rate will be defined as number of patients without ICANS of any grade divided by the number of evaluable patients. These rates will be reported along with the 95% exact binomial confidence interval. |
Up to CAR-T day +28
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Occurrence of severe CAR-T-associated neurotoxicity (ICANS of grade 3 or greater)
大体时间:Up to CAR-T day +28
|
Defined by ASTCT consensus criteria. Will be considered binary and the rate will be defined as number of patients with severe ICANS divided by the number of evaluable patients. These rates will be reported along with the 95% exact binomial confidence interval. |
Up to CAR-T day +28
|
|
Occurrence of severe cytokine release syndrome (cytokine release syndrome [CRS] of grade 3 or greater)
大体时间:Up to CAR-T day +28
|
Defined by ASTCT consensus criteria. Will be considered binary, and the rate will be defined as number of patients with severe CRS divided by the number of evaluable patients. These rates will be reported along with the 95% exact binomial confidence interval. |
Up to CAR-T day +28
|
|
Occurrence of adverse events related to natalizumab
大体时间:Up to CAR-T day +28
|
Treatment emergent adverse events will be tabulated, and the rate will be defined as number of patients with treatment emergent adverse events divided by the number of evaluable patients. These rates will be reported along with the 95% exact binomial confidence interval. |
Up to CAR-T day +28
|
|
Occurrence of complete response or partial response
大体时间:At CAR-T day +60
|
Assessed per Lugano classification on day +60 positron emission tomography/computed tomography. Will be defined as number of patients with treatment emergent adverse events divided by the number of evaluable patients. These rates will be reported along with the 95% exact binomial confidence interval. |
At CAR-T day +60
|
|
Occurrence of serious adverse events related to natalizumab
大体时间:Up to CAR-T day +28
|
Treatment emergent serious adverse events will be tabulated, and the rate will be defined as number of patients with treatment emergent adverse events divided by the number of evaluable patients. These rates will be reported along with the 95% exact binomial confidence interval. |
Up to CAR-T day +28
|
合作者和调查者
调查人员
- 首席研究员:Monalisa Ghosh、University of Michigan Rogel Cancer Center
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
- 肿瘤
- 免疫系统疾病
- 组织学类型的肿瘤
- 淋巴系统疾病
- 淋巴增生性疾病
- 免疫增生性疾病
- 淋巴瘤,非霍奇金
- 淋巴瘤,B细胞
- 淋巴瘤
- 半身和淋巴疾病
- 淋巴瘤,大 B 细胞,弥漫性
- 淋巴瘤,套细胞
- 氨基酸,肽和蛋白质
- 蛋白质
- 有机化学品
- 调查技术
- 临床实验室技术
- 诊断技术和程序
- 诊断
- 碳氢化合物
- 抗体,单克隆,人源化
- 抗体,单克隆
- 抗体
- 免疫球蛋白
- 免疫蛋白
- 血蛋白
- 血清球蛋白
- 球蛋白
- 化学技术,分析
- 频谱分析
- 磷酰胺芥末
- 氮芥末化合物
- 芥末化合物
- 碳氢化合物,卤素
- 磷酰胺
- 有机磷化合物
- 那他珠单抗
- 环磷酰胺
- 标本处理
- 磁共振光谱
- 氟达拉滨
- Brexucabtagene Autoleucel
- axibabtagene cileoleucel
- monoclonal antibody AN100226
其他研究编号
- UMCC 2026.011
- NCI-2026-05450 (注册表标识符:CTRP (Clinical Trial Reporting Program))
- HUM00289351 (其他标识符:University of Michigan Rogel Cancer Center)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.